Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes
Published inJournal of diabetes & metabolism, vol. 2, no. 4
Publication date2011
Citation (ISO format)
FOUQUERAY, Pascale et al. Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes. In: Journal of diabetes & metabolism, 2011, vol. 2, n° 4. doi: 10.4172/2155-6156.1000126
Main files (1)
Article (Published version)

Identifiers
- PID : unige:47301
- DOI : 10.4172/2155-6156.1000126
ISSN of the journal2155-6156